Since September 2017<unk>  is approved in the US for "adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones". In studies that compared fulvestrant plus<unk>  to fulvestrant plus placebo in breast cancer patients, progression-free survival under<unk>  therapy was 16.4 months on average, as compared to 9.3 months under the placebo arm.
Abemaciclib
Trilaciclib
Cemiplimab
Nirsevimab
Regdanvimab
Lirentelimab
Obiltoxaximab
Sotrovimab